---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053948"
form_type: "8-K"
ticker: null
cik: "0001805890"
company_name: "Fusion Pharmaceuticals Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:39:27.597929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fusion Q1 net loss $33.7M; AstraZeneca acquisition on track for Q2 2024

## Summary
- Net loss of $33.7M ($0.40/sh) vs $24.3M ($0.45/sh) in Q1 2023; R&D spend $21.3M.
- Cash and investments $283.1M as of March 31, 2024; expected to fund operations into Q4 2025.
- Definitive agreement to be acquired by AstraZeneca for up to $2.4B ($21/sh cash + $3 CVR); HSR clearance and Canadian Competition Bureau no-action received; expected close Q2 2024.
- Interim data for FPI-2265 in mCRPC presented at AACR 2024; Phase 2 dose optimization trial to start Q2 2024, Phase 3 registrational trial planned for 2025.
- FPI-1434 Phase 1 trial shows encouraging early findings; no DLTs in 25 kBq/kg cohort; stable disease and anti-tumor activity observed.

## SEC filing metadata
- accession: 0000950170-24-053948
- form_type: 8-K
- cik: 0001805890
- company_name: Fusion Pharmaceuticals Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/0000950170-24-053948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/fusn-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053948
- JSON: https://secwatch.observer/filing/0000950170-24-053948.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053948.txt

## Key facts
- Earnings Releases
  Fusion Pharmaceuticals Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Fusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/0000950170-24-053948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.